Sugi Predict

Sugi Predict / Compounds / SCHEMBL18924130

SCHEMBL18924130

SCHEMBL18924130

C[C@H](N)C(=O)NCC(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 1/20 0.39
▸ PTPRC P08575 2/20 0.38
▸ TERT O14746 1/20 0.38
▸ CTSS P25774 4/20 0.37
▸ CTSK P43235 4/20 0.37
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA7 P43166 1/20 0.36
▸ MAOA P21397 1/20 0.36
▸ MAOB P27338 1/20 0.36
▸ CTSL P07711 1/20 0.36
▸ CTSB P07858 1/20 0.36
▸ GAA P10253 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ MAPT P10636 2/20 0.34
▸ TDP1 Q9NUW8 2/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27072723 1.00 CYP2D6 (0.39) CYP2D6PTPRCTERTCTSSCTSK
SCHEMBL29590221 0.87 KMT2A (0.39) CYP2D6PTPRCCTSSCTSKCA1
SCHEMBL22987336 0.85 CYP2D6 (0.41) CYP2D6PTPRCCTSSCTSKCA1
SCHEMBL12017898 0.84 CYP2D6 (0.41) CYP2D6PTPRCCTSSCTSKCA1
SCHEMBL30365142 0.83 CTSS (0.52) CTSSCTSKCTSLCTSBGAA
SCHEMBL29037226 0.82 MEN1 (0.46) CYP2D6PTPRCCTSSCTSKCA1
SCHEMBL16000761 0.82 TET2 (0.48) TERTCA1CA2GAAMAPT
SCHEMBL5641925 0.82 TET2 (0.48) TERTCA1CA2GAAMAPT
SCHEMBL26296364 0.82 TET2 (0.48) TERTCA1CA2GAAMAPT
SCHEMBL20529467 0.81 CAPN1 (0.44) CYP2D6TERTCA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124212-A1 MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF IMMUNOGEN INC (US) 2026-05-07 — — US disclosed
US-20260062421-A1 NOVEL PROCESSES FOR PREPARING CAMPTOTHECIN DERIVATIVES IMMUNOGEN INC (US) 2026-03-05 — — US disclosed
US-12390471-B2 Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof IMMUNOGEN, INC. (US) 2025-08-19 — — US disclosed
WO-2024025890-A1 NOVEL PROCESSES FOR PREPARING CAMPTOTHECIN DERIVATIVES IMMUNOGEN, INC. (US) 2024-02-01 — — WO disclosed
CN-116785451-A Maytansinoid derivatives with self-cleaving peptide linker and conjugates thereof 伊缪诺金公司 2023-09-22 — — CN disclosed
CN-116785450-A Maytansinoid derivatives with self-cleaving peptide linker and conjugates thereof 伊缪诺金公司 2023-09-22 — — CN disclosed
CN-110366431-B Maytansinoid derivatives with self-cleaving peptide linker and conjugates thereof 伊缪诺金公司 2023-07-18 — — CN disclosed
CN-112020492-B Method for producing amide compound 学校法人中部大学 2023-05-05 — — CN disclosed
US-20220111067-A1 MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF IMMUNOGEN SWITZERLAND GMBH (CH) 2022-04-14 — — US disclosed
US-11135308-B2 Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof IMMUNOGEN, INC. (US) 2021-10-05 — — US disclosed
US-20210275685-A1 IMMUNOCONJUGATES TARGETING ADAM9 AND METHODS OF USE THEREOF MACROGENICS, INC. 2021-09-09 — — US disclosed
US-10792372-B2 Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof IMMUNOGEN, INC. (US) 2020-10-06 — — US disclosed
US-10722588-B2 Cytotoxic benzodiazepine derivatives IMMUNOGEN, INC. (US) 2020-07-28 — — US disclosed
US-20200197531-A1 MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF IMMUNOGEN, INC. 2020-06-25 — — US disclosed
US-20190269786-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2019-09-05 — — US disclosed
US-10238751-B2 Cytotoxic benzodiazepine derivatives IMMUNOGEN, INC. (US) 2019-03-26 — — US disclosed
US-20170340748-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2017-11-30 — — US disclosed
US-9669102-B2 Cytotoxic benzodiazepine derivatives IMMUNOGEN, INC. (US) 2017-06-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062421-A1 NOVEL PROCESSES FOR PREPARING CAMPTOTHECIN DERIVATIVES TOP2A, TOP1, TOP2B CYP2D6 953/4885PTPRC 2129/4885TERT 1561/4885
US-10238751-B2 Cytotoxic benzodiazepine derivatives GABRA6, GABBR1, GABRA5 CYP2D6 90/4885PTPRC 3267/4885TERT 4745/4885
US-20200197531-A1 MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF VIP, AREG, MIF CYP2D6 4317/4885PTPRC 2254/4885TERT 4386/4885
US-12390471-B2 Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof VIP, AREG, MIF CYP2D6 4317/4885PTPRC 2254/4885TERT 4386/4885
US-10722588-B2 Cytotoxic benzodiazepine derivatives GABRA6, GABBR1, GABRA5 CYP2D6 90/4885PTPRC 3267/4885TERT 4745/4885
US-20210275685-A1 IMMUNOCONJUGATES TARGETING ADAM9 AND METHODS OF USE THEREOF ADAM9, ADAM33, ADAM12 CYP2D6 673/4885PTPRC 1733/4885TERT 3129/4885
US-20220111067-A1 MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF VIP, AREG, MIF CYP2D6 4317/4885PTPRC 2254/4885TERT 4386/4885
US-20190269786-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES GABRA6, GABBR1, GABRA5 CYP2D6 90/4885PTPRC 3267/4885TERT 4745/4885
US-11135308-B2 Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof VIP, AREG, MIF CYP2D6 4317/4885PTPRC 2254/4885TERT 4386/4885
US-10792372-B2 Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof VIP, AREG, MIF CYP2D6 4317/4885PTPRC 2254/4885TERT 4386/4885
US-20170340748-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES GABRA6, GABBR1, GABRA5 CYP2D6 90/4885PTPRC 3267/4885TERT 4745/4885
US-20260124212-A1 MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF VEGFA, VIP, AREG CYP2D6 2881/4885PTPRC 2050/4885TERT 4527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.